GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Redwood Pharma AB (OSTO:REDW) » Definitions » Profitability Rank

Redwood Pharma AB (OSTO:REDW) Profitability Rank : 1 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Redwood Pharma AB Profitability Rank?

Redwood Pharma AB has the Profitability Rank of 1. It has had trouble to make a profit.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Redwood Pharma AB's Operating Margin % for the quarter that ended in Mar. 2024 was %. As of today, Redwood Pharma AB's Piotroski F-Score is 1.


Competitive Comparison of Redwood Pharma AB's Profitability Rank

For the Biotechnology subindustry, Redwood Pharma AB's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Redwood Pharma AB's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Redwood Pharma AB's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Redwood Pharma AB's Profitability Rank falls into.



Redwood Pharma AB Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Redwood Pharma AB has the Profitability Rank of 1. It has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Redwood Pharma AB's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=-3.396 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

Warning Sign:

Piotroski F-Score of 1 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Redwood Pharma AB has an F-score of 1. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


Redwood Pharma AB Profitability Rank Related Terms

Thank you for viewing the detailed overview of Redwood Pharma AB's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Redwood Pharma AB (OSTO:REDW) Business Description

Traded in Other Exchanges
Address
Ringvagen 100E, 9th Floor, Stockholm, SWE, 118 60
Redwood Pharma AB is engaged in developing new ophthalmic pharmaceutical therapies for unmet market needs. Its development product is a new therapy to treat chronic Dry Eye Disease (DED) in post-menopausal women.

Redwood Pharma AB (OSTO:REDW) Headlines

No Headlines